Contribute Try STAT+ Today

After months of delay, Health Canada has released a final version of new regulations that are designed to cut prescription drug spending by the Canadian government, although the effort continued to draw harsh criticism from the pharmaceutical industry.

The changes will alter a decades-old framework that has been used by the agency’s Patented Medicine Prices Review Board to set prices. Notably, the PMPRB will no longer consider prices in the U.S. and Switzerland, which have some of the world’s highest for prescription medicines, when trying to set maximum prices that drug makers may charge in Canada.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy